Covidien Announces FDA 510(k) Clearance of New LigaSure(TM) Instrument
BOULDER, Colo., Feb 16, 2011 (BUSINESS WIRE) --
Covidien (NYSE: COV), a leading global provider of healthcare products, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the LigaSure(TM) Curved, Small Jaw, Open Sealer/Divider surgical instrument. The device is indicated for use in general surgery and will be available in the United States this quarter.
The LigaSure Curved, Small Jaw, Open Sealer/Divider, the newest addition to the LigaSure family of advanced surgical cutting/sealing devices, provides an integrated cutting mechanism independent of sealing, leaving the critical cutting decisions in the hands of the surgeon. Its multi-functional design also provides for blunt dissection and an enhanced, more efficient experience for the surgeon, especially in confined surgical spaces. A primary feature of this new LigaSure device is a low-temperature profile and minimal thermal spread to surrounding tissues.
The proven LigaSure technology, powered by the ForceTriadTM energy platform, provides surgeons with a continuous output of energy, monitoring the tissue and making real-time adjustments 3,333 times/second to seal vessel walls. LigaSure technology has been in use for 12 years, and is utilized in more than one million procedures around the world each year.
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2010 revenue of $10.4 billion, Covidien has approximately 42,000 employees worldwide in more than 60 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.